DermaVue SuperHuman Program
GLP-1 Injections for Belly Fat & Visceral Fat Loss in India
Target the Hidden Fat That Diets Can't Touch — Doctor-Supervised Treatment for the Skinny-Fat Indian Phenotype
Doctor Prescription Required · Book a Consultation
The Hidden Epidemic
The Problem Diets Can't Solve: Why Indians Gain Fat Differently
You eat clean. You exercise. Your weight is "normal." Yet your belly won't budge, your blood sugar is creeping up, and your doctor says everything looks fine on paper. Sound familiar?
The truth is, standard BMI charts were designed for European populations. They miss what researchers call the Asian Indian Phenotype — a genetic tendency to store dangerous visceral fat around internal organs, even at a "healthy" weight.
| Person | BMI | Body Fat % |
|---|---|---|
| Indian Doctor, Age 35 | 22.3 | 21.2% |
| European Doctor, Age 35 | 22.3 | 9.1% |
Same BMI. Completely different health risk. (Source: The Lancet)
This is the Asian Indian Phenotype: higher body fat percentage, more visceral fat deposition, greater insulin resistance, and elevated cardiovascular risk — all hidden behind a normal BMI number. It's the reason an Indian man with BMI 23 can have the metabolic profile of a European man with BMI 30.
Diet and exercise alone cannot selectively target visceral fat. Your body is hormonally programmed to hold onto it. That's where GLP-1 receptor agonist therapy changes the equation.
Self-Assessment
Are You Skinny Fat? Indian Risk Indicators
Indian BMI cutoffs are significantly lower than international standards. What's "normal" globally may already be overweight for you.
| Category | Indian BMI | International BMI |
|---|---|---|
| Normal | 18.0 – 22.9 | 18.5 – 24.9 |
| Overweight | 23.0 – 24.9 | 25.0 – 29.9 |
| Obese | ≥ 25.0 | ≥ 30.0 |
| Waist Circumference | At-Risk Threshold |
|---|---|
| Men | > 85 cm (33.5 inches) |
| Women | > 75 cm (29.5 inches) |
You May Be Skinny Fat If:
The Science
What Is GLP-1 and Why Does It Work for Belly Fat?
GLP-1 (Glucagon-Like Peptide-1) is a hormone naturally produced in your gut after eating. It tells your brain you're full, slows stomach emptying, and regulates blood sugar. GLP-1 receptor agonist medications amplify this signal — and specifically target visceral fat around your organs.
Unlike diet pills that simply suppress appetite, GLP-1 medications work through four distinct mechanisms that address the root causes of stubborn belly fat in Indian patients.
Brain
Reduces hunger signals and stops food cravings. You feel satisfied with less food — naturally, not through willpower.
Stomach
Slows gastric emptying so food stays longer. You feel full for hours after a normal-sized meal.
Liver & Fat
Targets visceral belly fat specifically. Reduces liver fat and improves lipid markers within weeks.
Pancreas
Improves insulin sensitivity and regulates blood sugar. Addresses the metabolic dysfunction driving fat storage.
Treatment Options
GLP-1 Medications Available in India for Belly Fat
Your dermatologist-led care team selects the right GLP-1 medication based on your metabolic profile and preferences.
| Your Profile | Recommended GLP-1 | Format |
|---|---|---|
| BMI 23–27 with belly fat | Semaglutide (Ozempic) | Weekly injection |
| BMI >27 or high insulin resistance | Tirzepatide (Mounjaro) | Weekly injection |
| Needle-phobic | Oral Semaglutide (Rybelsus) | Daily tablet |
| Generic option available | Generic Semaglutide | Weekly injection |
Why It's Different
Why Belly Fat Needs Medical Treatment (Not Just Diet)
If willpower alone could fix visceral fat, you wouldn't be reading this. Here's why conventional approaches fail — and what actually works.
| Approach | What It Does | Why It Fails for Visceral Fat |
|---|---|---|
| Calorie Counting | Cuts total calorie intake | Doesn't fix hormonal fat storage signals |
| Gym / Exercise | Burns some calories, builds muscle | Cannot selectively target internal organ fat |
| Intermittent Fasting | Restricts eating windows | Causes muscle loss and rebound hunger |
| Ayurveda / Herbs | Various traditional claims | No clinical evidence for visceral fat reduction |
What GLP-1 Does That Nothing Else Can
GLP-1 receptor agonists work at the hormonal level to reprogram your body's fat storage signals. Clinical evidence shows:
- 14–22% total body weight loss in clinical trials
- Preferential reduction of visceral (belly) fat over subcutaneous fat
- Improved insulin sensitivity within 4–8 weeks
- Reduced liver fat (NAFLD improvement) in 60–70% of patients
- Sustained appetite regulation — not willpower, but biology
Our Advantage
Why DermaVue for GLP-1 Treatment?
Not all GLP-1 programs are equal. DermaVue's SuperHuman Program is the only dermatologist-led weight loss program in South India with built-in skin protection.
Board-Certified Dermatologists (IADVL)
Your skin changes during weight loss. Our dermatologists monitor and protect your skin throughout the GLP-1 journey — preventing sagging, stretch marks, and dullness.
US-Trained Medical Director
Dr. Rejeesh Menon brings international training and evidence-based protocols. Every treatment plan is reviewed and approved by our medical director.
Dietitian-Led Nutrition Program
Weekly consultations with certified dietitians. Protein optimization, micronutrient planning, and meal strategies designed specifically for GLP-1 patients.
Face-Saver Protocol
The only GLP-1 program in Kerala with built-in "Ozempic Face" prevention. Targeted facial treatments, collagen support, and volume preservation strategies from day one.
7 Locations Across South India
Thiruvananthapuram, Kollam, Thiruvalla, Kottayam, Kochi · Aluva, Thrissur, Coimbatore — convenient access across Kerala and Tamil Nadu with consistent protocols at every location.
Common Questions
Frequently Asked Questions
Everything you need to know about GLP-1 therapy for belly fat at DermaVue.
-
GLP-1 receptor agonist therapy uses medications that mimic the natural GLP-1 hormone to reduce appetite, slow digestion, and target visceral belly fat. Available as weekly injections (Ozempic, Mounjaro) or daily oral tablets (Rybelsus). These medications were originally developed for type 2 diabetes and are now approved for weight management.
-
Yes, with proper medical screening. Indian guidelines define overweight as BMI ≥ 23 (compared to 25 internationally). GLP-1 is particularly effective for the thin-fat phenotype with central obesity at normal Western BMI cutoffs. Your DermaVue doctor will assess your metabolic profile, waist circumference, and blood markers before prescribing.
-
Clinical trials show 14–22% total body weight loss over 12–18 months. Individual results depend on medication choice, adherence, diet, and exercise. Indian patients with the skinny-fat phenotype often see dramatic improvements in waist circumference and metabolic markers even with modest overall weight loss.
-
Common side effects include nausea (44%), vomiting (24%), and constipation (24%). These typically resolve within 4–8 weeks as your body adjusts. DermaVue's gradual dose titration protocol minimizes side effects — we start low and increase slowly, with weekly check-ins during the first month.
-
Most patients notice reduced appetite within the first week. Visible weight changes typically occur by weeks 4–6. Significant results (10–20% body weight reduction) are seen by months 3–6 depending on the medication and individual response.
-
Yes, type 2 diabetes is actually a primary indication for GLP-1 medications. They improve both weight and blood sugar control simultaneously. Your doctor will adjust your existing diabetes medications accordingly to prevent hypoglycaemia. GLP-1 is not recommended for type 1 diabetes.
-
Some weight regain is possible, which is why the SuperHuman Program focuses on building sustainable habits alongside medication. Protein optimization, resistance training, and behavioral changes help maintain results long-term. Many patients transition to a lower maintenance dose rather than stopping completely.
DERMAVUE SUPERHUMAN PROGRAM
Ready to Start Your SuperHuman Journey?
Talk to a doctor — free 10-minute WhatsApp consultation
★ 4.8 rating · 7,200+ patients · Dermatologist-led program
